{"data":[{"accessionNo":"0001875620-26-000015","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Sands Capital Alternatives, LLC","reportingCik":null,"personType":"OO","sharesOwned":2289271,"percentOfClass":5.3,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001875620-26-000015","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"SANDS FRANK M.","reportingCik":null,"personType":"IN,HC","sharesOwned":2289271,"percentOfClass":5.3,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001875620-26-000015","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Sands Capital Life Sciences Pulse Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2289271,"percentOfClass":5.3,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-26-062728","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Kenneth Griffin","reportingCik":null,"personType":"HC,IN","sharesOwned":13,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-26-062728","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel Securities GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":13,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-26-062728","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel Securities Group LP","reportingCik":null,"personType":"HC,PN","sharesOwned":13,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-26-062728","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel Securities LLC","reportingCik":null,"personType":"BD,OO","sharesOwned":13,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-26-062728","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-26-062728","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel Advisors Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-26-062728","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel Advisors LLC","reportingCik":null,"personType":"IA,HC,OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001346824-26-000116","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"ACRIVON THERAPEUTICS, INC.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-22","reportingPerson":"RA Capital Management, L.P.","reportingCik":"0001346824","personType":"IA,PN","sharesOwned":12284906,"percentOfClass":28.8,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001346824-26-000116","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"ACRIVON THERAPEUTICS, INC.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-22","reportingPerson":"Peter Kolchinsky","reportingCik":"0001384859","personType":"HC,IN","sharesOwned":12284906,"percentOfClass":28.8,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001346824-26-000116","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"ACRIVON THERAPEUTICS, INC.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-22","reportingPerson":"Rajeev Shah","reportingCik":"0001619841","personType":"HC,IN","sharesOwned":12284906,"percentOfClass":28.8,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001346824-26-000116","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"ACRIVON THERAPEUTICS, INC.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-22","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":"0001315082","personType":"PN","sharesOwned":11803094,"percentOfClass":27.7,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001346824-26-000081","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001781174","issuerName":"ACRIVON THERAPEUTICS, INC.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-19","reportingPerson":"Rajeev Shah","reportingCik":"0001619841","personType":"HC,IN","sharesOwned":8396018,"percentOfClass":21.6,"filedAt":"2026-03-23","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001346824-26-000081","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001781174","issuerName":"ACRIVON THERAPEUTICS, INC.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-19","reportingPerson":"RA Capital Management, L.P.","reportingCik":"0001346824","personType":"IA,PN","sharesOwned":8396018,"percentOfClass":21.6,"filedAt":"2026-03-23","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001346824-26-000081","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001781174","issuerName":"ACRIVON THERAPEUTICS, INC.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-19","reportingPerson":"Peter Kolchinsky","reportingCik":"0001384859","personType":"HC,IN","sharesOwned":8396018,"percentOfClass":21.6,"filedAt":"2026-03-23","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001346824-26-000081","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001781174","issuerName":"ACRIVON THERAPEUTICS, INC.","ticker":"ACRV","cusip":"004890109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-19","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":"0001315082","personType":"PN","sharesOwned":7914206,"percentOfClass":20.4,"filedAt":"2026-03-23","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-115063","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-11-14","reportingPerson":"Kenneth Griffin","reportingCik":null,"personType":"HC,IN","sharesOwned":1721867,"percentOfClass":5.5,"filedAt":"2025-11-21","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-115063","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-11-14","reportingPerson":"Citadel GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":1541326,"percentOfClass":4.9,"filedAt":"2025-11-21","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-115063","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-11-14","reportingPerson":"Citadel Advisors Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":1541326,"percentOfClass":4.9,"filedAt":"2025-11-21","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-115063","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-11-14","reportingPerson":"Citadel Advisors LLC","reportingCik":null,"personType":"IA,HC,OO","sharesOwned":1541326,"percentOfClass":4.9,"filedAt":"2025-11-21","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-115063","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-11-14","reportingPerson":"Citadel Securities LLC","reportingCik":null,"personType":"BD,OO","sharesOwned":180541,"percentOfClass":0.6,"filedAt":"2025-11-21","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-115063","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-11-14","reportingPerson":"Citadel Securities Group LP","reportingCik":null,"personType":"HC,PN","sharesOwned":180541,"percentOfClass":0.6,"filedAt":"2025-11-21","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-115063","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-11-14","reportingPerson":"Citadel Securities GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":180541,"percentOfClass":0.6,"filedAt":"2025-11-21","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-112501","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Kenneth Griffin","reportingCik":null,"personType":"HC,IN","sharesOwned":1541365,"percentOfClass":4.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-112501","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Advisors LLC","reportingCik":null,"personType":"IA,HC,OO","sharesOwned":1541326,"percentOfClass":4.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-112501","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Advisors Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":1541326,"percentOfClass":4.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-112501","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":1541326,"percentOfClass":4.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-112501","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Securities Group LP","reportingCik":null,"personType":"HC,PN","sharesOwned":39,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-112501","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Securities GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":39,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"},{"accessionNo":"0001104659-25-112501","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781174","issuerName":"Acrivon Therapeutics, Inc.","ticker":"ACRV","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Securities LLC","reportingCik":null,"personType":"BD,OO","sharesOwned":39,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/acrv"}],"updatedAt":"2026-11-04T01:28:36.445Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/acrv","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}